Quarterly report · Q2
4583.TEDINET S100RN56
Period2023-01-01 → 2023-06-30
Filed2023-08-09
StandardJapan GAAP
ConsolidatedNo
Data checks12 of 12 passed
Amended by S100S9VE (2023-11-13).
Key figures · 45
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥359m | 2023-01-01 → 2023-06-30 | Standalone | Net sales |
| Revenue | ¥631m | 2022-01-01 → 2022-12-31 | Standalone | Net sales (5-year summary) |
| Revenue | ¥278m | 2022-01-01 → 2022-06-30 | Standalone | Net sales |
| Operating income | −¥659m | 2023-01-01 → 2023-06-30 | Standalone | Operating income |
| Operating income | −¥779m | 2022-01-01 → 2022-06-30 | Standalone | Operating income |
| Ordinary income | −¥662m | 2023-01-01 → 2023-06-30 | Standalone | Ordinary income |
| Ordinary income | −¥1.2bn | 2022-01-01 → 2022-12-31 | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥769m | 2022-01-01 → 2022-06-30 | Standalone | Ordinary income |
| Profit before tax | −¥661m | 2023-01-01 → 2023-06-30 | Standalone | Income before income taxes |
| Profit before tax | −¥769m | 2022-01-01 → 2022-06-30 | Standalone | Income before income taxes |
| Net income | −¥664m | 2023-01-01 → 2023-06-30 | Standalone | Profit loss |
| Net income | −¥1.2bn | 2022-01-01 → 2022-12-31 | Standalone | Net income loss (5-year summary) |
| Net income | −¥771m | 2022-01-01 → 2022-06-30 | Standalone | Profit loss |
| Total assets | ¥1.7bn | at 2023-06-30 | Standalone | Assets |
| Total assets | ¥2.2bn | at 2022-12-31 | Standalone | Assets |
| Total assets | ¥1.9bn | at 2022-06-30 | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥541m | at 2023-06-30 | Standalone | Liabilities |
| Total liabilities | ¥425m | at 2022-12-31 | Standalone | Liabilities |
| Net assets / equity | ¥1.1bn | at 2023-06-30 | Standalone | Net assets |
| Net assets / equity | ¥1.8bn | at 2022-12-31 | Standalone | Net assets |
| Net assets / equity | ¥1.5bn | at 2022-06-30 | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥1.2bn | at 2023-06-30 | Standalone | Cash and deposits |
| Cash and deposits | ¥1.7bn | at 2022-12-31 | Standalone | Cash and deposits |
| Cash & equivalents | ¥1.2bn | at 2023-06-30 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥1.7bn | at 2022-12-31 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥1.5bn | at 2022-06-30 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥1.8bn | at 2021-12-31d | Standalone | Cash and cash equivalents |
| Operating cash flow | −¥595m | 2023-01-01 → 2023-06-30 | Standalone | Net cash provided by used in operating activities |
| Operating cash flow | −¥1.2bn | 2022-01-01 → 2022-12-31 | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥660m | 2022-01-01 → 2022-06-30 | Standalone | Net cash provided by used in operating activities |
| Investing cash flow | ¥82,000 | 2023-01-01 → 2023-06-30 | Standalone | Net cash provided by used in investment activities |
| Financing cash flow | ¥113m | 2023-01-01 → 2023-06-30 | Standalone | Net cash provided by used in financing activities |
| Financing cash flow | ¥1.1bn | 2022-01-01 → 2022-12-31 | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥341m | 2022-01-01 → 2022-06-30 | Standalone | Net cash provided by used in financing activities |
| EPS (basic) | ¥-13.7 | 2023-01-01 → 2023-06-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-9 | 2023-04-01 → 2023-06-30d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-28.26 | 2022-01-01 → 2022-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-18.17 | 2022-01-01 → 2022-06-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-6.53 | 2022-04-01 → 2022-06-30d | Standalone | Basic earnings loss per share (5-year summary) |
| Equity ratio | 67.2% | at 2023-06-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 80.2% | at 2022-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 75.3% | at 2022-06-30 | Standalone | Equity to asset ratio (5-year summary) |
| Shares issued | 48,503,800 | at 2023-06-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 48,423,500 | at 2022-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 43,057,600 | at 2022-06-30 | Standalone | Total number of issued shares (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 16
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | segment profit | 2023-01-01 → 2023-06-30 | −¥266m |
| jpcrp040300-q2r_E26096-000Drug Discovery And Developmentreportable segment | segment profit | 2023-01-01 → 2023-06-30 | −¥602m |
| jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segment | revenue | 2023-01-01 → 2023-06-30 | ¥359m |
| jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segment | revenue external | 2023-01-01 → 2023-06-30 | ¥359m |
| jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segment | segment profit | 2023-01-01 → 2023-06-30 | ¥209m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-01-01 → 2023-06-30 | ¥359m |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-01-01 → 2023-06-30 | ¥359m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-01-01 → 2023-06-30 | −¥393m |
| Reconciling Itemsreconciling | segment profit | 2022-01-01 → 2022-06-30 | −¥239m |
| jpcrp040300-q2r_E26096-000Drug Discovery And Developmentreportable segment | segment profit | 2022-01-01 → 2022-06-30 | −¥691m |
| jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segment | revenue | 2022-01-01 → 2022-06-30 | ¥278m |
| jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segment | revenue external | 2022-01-01 → 2022-06-30 | ¥278m |
| jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segment | segment profit | 2022-01-01 → 2022-06-30 | ¥151m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-01-01 → 2022-06-30 | ¥278m |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-01-01 → 2022-06-30 | ¥278m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-01-01 → 2022-06-30 | −¥540m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 444
| Item | Context | Value | Unit |
|---|---|---|---|
| Non operating income | CurrentYTDDuration_NonConsolidatedMember | 424000 | JPY |
| Interest expenses noe | Prior1YTDDuration_NonConsolidatedMember | 645000 | JPY |
| Interest expenses noe | CurrentYTDDuration_NonConsolidatedMember | 910000 | JPY |
| Stock issuance cost noe | Prior1YTDDuration_NonConsolidatedMember | 1416000 | JPY |
| Stock issuance cost noe | CurrentYTDDuration_NonConsolidatedMember | 940000 | JPY |
| Share based payment expenses noe | Prior1YTDDuration_NonConsolidatedMember | － | JPY |
| Share based payment expenses noe | CurrentYTDDuration_NonConsolidatedMember | 654000 | JPY |
| Foreign exchange losses noe | Prior1YTDDuration_NonConsolidatedMember | 3339000 | JPY |
| Foreign exchange losses noe | CurrentYTDDuration_NonConsolidatedMember | 808000 | JPY |
| Other noe | Prior1YTDDuration_NonConsolidatedMember | 286000 | JPY |
| Other noe | CurrentYTDDuration_NonConsolidatedMember | 0 | JPY |
| Non operating expenses | Prior1YTDDuration_NonConsolidatedMember | 5687000 | JPY |
| Non operating expenses | CurrentYTDDuration_NonConsolidatedMember | 3314000 | JPY |
| Ordinary income | Prior1YTDDuration_NonConsolidatedMember | -768686000 | JPY |
| Ordinary income | CurrentYTDDuration_NonConsolidatedMember | -662139000 | JPY |
| Gain on sales of noncurrent assets ei | Prior1YTDDuration_NonConsolidatedMember | － | JPY |
| Gain on sales of noncurrent assets ei | CurrentYTDDuration_NonConsolidatedMember | 73000 | JPY |
| Gain on reversal of subscription rights to shares ei | Prior1YTDDuration_NonConsolidatedMember | 186000 | JPY |
| Gain on reversal of subscription rights to shares ei | CurrentYTDDuration_NonConsolidatedMember | 930000 | JPY |
| Extraordinary income | Prior1YTDDuration_NonConsolidatedMember | 186000 | JPY |
| Extraordinary income | CurrentYTDDuration_NonConsolidatedMember | 1003000 | JPY |
| Loss on sales of noncurrent assets el | Prior1YTDDuration_NonConsolidatedMember | － | JPY |
| Loss on sales of noncurrent assets el | CurrentYTDDuration_NonConsolidatedMember | 14000 | JPY |
| Extraordinary loss | Prior1YTDDuration_NonConsolidatedMember | － | JPY |
| Extraordinary loss | CurrentYTDDuration_NonConsolidatedMember | 14000 | JPY |
| Income before income taxes | Prior1YTDDuration_NonConsolidatedMember | -768500000 | JPY |
| Income before income taxes | CurrentYTDDuration_NonConsolidatedMember | -661150000 | JPY |
| Income taxes current | Prior1YTDDuration_NonConsolidatedMember | 2505000 | JPY |
| Income taxes current | CurrentYTDDuration_NonConsolidatedMember | 2505000 | JPY |
| Income taxes | Prior1YTDDuration_NonConsolidatedMember | 2505000 | JPY |
| Income taxes | CurrentYTDDuration_NonConsolidatedMember | 2505000 | JPY |
| Profit loss | Prior1YTDDuration_NonConsolidatedMember | -771005000 | JPY |
| Profit loss | CurrentYTDDuration_NonConsolidatedMember | -663655000 | JPY |
| Income before income taxes | Prior1YTDDuration_NonConsolidatedMember | -768500000 | JPY |
| Income before income taxes | CurrentYTDDuration_NonConsolidatedMember | -661150000 | JPY |
| Depreciation and amortization ope cf | Prior1YTDDuration_NonConsolidatedMember | 762000 | JPY |
| Depreciation and amortization ope cf | CurrentYTDDuration_NonConsolidatedMember | 611000 | JPY |
| Decrease increase in notes and accounts receivable trade ope cf | Prior1YTDDuration_NonConsolidatedMember | -42946000 | JPY |
| Decrease increase in notes and accounts receivable trade ope cf | CurrentYTDDuration_NonConsolidatedMember | 18308000 | JPY |
| Decrease increase in inventories ope cf | Prior1YTDDuration_NonConsolidatedMember | -6984000 | JPY |
| Decrease increase in inventories ope cf | CurrentYTDDuration_NonConsolidatedMember | 11739000 | JPY |
| Decrease increase in advance payments ope cf | Prior1YTDDuration_NonConsolidatedMember | 157194000 | JPY |
| Decrease increase in advance payments ope cf | CurrentYTDDuration_NonConsolidatedMember | 3874000 | JPY |
| Decrease increase in consumption taxes refund receivable ope cf | Prior1YTDDuration_NonConsolidatedMember | 15397000 | JPY |
| Decrease increase in consumption taxes refund receivable ope cf | CurrentYTDDuration_NonConsolidatedMember | 23394000 | JPY |
| Increase decrease in notes and accounts payable trade ope cf | Prior1YTDDuration_NonConsolidatedMember | 16280000 | JPY |
| Increase decrease in notes and accounts payable trade ope cf | CurrentYTDDuration_NonConsolidatedMember | 4197000 | JPY |
| Increase decrease in accounts payable other ope cf | Prior1YTDDuration_NonConsolidatedMember | 8985000 | JPY |
| Increase decrease in accounts payable other ope cf | CurrentYTDDuration_NonConsolidatedMember | 710000 | JPY |
| Increase decrease in accrued expenses ope cf | Prior1YTDDuration_NonConsolidatedMember | -11422000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |